Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C3390)
◆英語タイトル:Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3390
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company offers plazomicin for the treatment of serious bacterial infections including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae. Its pipeline products include C-scape, novel aminoglycoside, and others. Achaogen’s C-Scape is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor that can treat patients with complex urinary tract infections due to MDR pathogens. The company collaborates with antibacterial drug development companies and academic researchers in the field of antibiotic pharmacology. Achaogen is headquartered in San Francisco, California, the US.

Achaogen Inc (AKAO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achaogen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Achaogen Raises US$19 Million In Venture Financing 11
Partnerships 12
Achaogen Enters into Agreement with Microgenics 12
Licensing Agreements 13
Achaogen Enters into Licensing Agreement with Crystal Bioscience 13
Achaogen Enters into Licensing Agreement with Trianni 14
Equity Offering 15
Achaogen to Raise up to USD50 Million in Public Offering of Shares 15
Achaogen Raises USD112.5 Million in Public Offering of Shares 16
Achaogen to Raise USD10 Million in Private Placement of Shares 18
Achaogen Receives USD5.3 Million in Public Offering of Shares 19
Achaogen Raises USD101 Million in Public Offering of Shares 20
Achaogen Raises USD25 Million in Private Placement of Shares 22
Achaogen Completes IPO For US$82.8 Million 24
Achaogen Inc – Key Competitors 25
Achaogen Inc – Key Employees 26
Achaogen Inc – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Financial Announcements 28
Aug 06, 2018: Achaogen reports second quarter 2018 financial results and provides corporate update 28
May 04, 2018: Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 27, 2018: Achaogen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Nov 08, 2017: Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Aug 03, 2017: Achaogen Reports Second Quarter 2017 Financial Results and Provides Corporate Update 34
May 08, 2017: Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update 36
Mar 14, 2017: Achaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 38
Corporate Communications 40
Dec 11, 2017: Achaogen Appoints Blake Wise Chief Executive Officer 40
Sep 18, 2017: Achaogen Adds Liz Bhatt as Chief Business Officer 41
Jul 13, 2017: Achaogen Appoints Dr. Karen Bernstein to its Board of Directors 42
Feb 27, 2017: Achaogen Adds Janet Dorling as Chief Commercial Officer 43
Feb 23, 2017: Achaogen Announces Leadership Promotions 44
Jan 05, 2017: Achaogen appoints new board member 45
Government and Public Interest 46
May 05, 2017: Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria 46
Product News 47
07/25/2017: Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections 47
Mar 01, 2017: Achaogen Highlights Emerging Pipeline of Antibacterials Including a new Orally-Administered Antibiotic Clinical Candidate at Company’s R&D Day 48
Clinical Trials 49
Jan 02, 2018: Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape 49
Sep 28, 2017: Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape 51
Jun 01, 2017: Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Achaogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achaogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achaogen Raises US$19 Million In Venture Financing 11
Achaogen Enters into Agreement with Microgenics 12
Achaogen Enters into Licensing Agreement with Crystal Bioscience 13
Achaogen Enters into Licensing Agreement with Trianni 14
Achaogen to Raise up to USD50 Million in Public Offering of Shares 15
Achaogen Raises USD112.5 Million in Public Offering of Shares 16
Achaogen to Raise USD10 Million in Private Placement of Shares 18
Achaogen Receives USD5.3 Million in Public Offering of Shares 19
Achaogen Raises USD101 Million in Public Offering of Shares 20
Achaogen Raises USD25 Million in Private Placement of Shares 22
Achaogen Completes IPO For US$82.8 Million 24
Achaogen Inc, Key Competitors 25
Achaogen Inc, Key Employees 26

List of Figures
Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achaogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achaogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Achaogen Inc (AKAO):製薬・医療:M&Aディール及び事業提携情報(Achaogen Inc (AKAO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆